Literature DB >> 11279963

Central nervous system superficial siderosis, headache, and epilepsy.

S Iannaccone1, V Golzi, B Sferrazza, F de Rino, S Smirne, L Ferini-Strambi.   

Abstract

Almost 95 cases of superficial siderosis of the central nervous system have been reported in the literature. These patients showed a clinical syndrome characterized by ataxia, deafness, pyramidal system involvement, and mental deterioration with xanthochromic cerebrospinal fluid and neuroradiological findings of hemosiderin deposits. About 30% of the patients had headache as an accompanying symptom. In the present case report, we describe a 33-year-old man with the typical clinical features of superficial siderosis, who complained, since aged 8, of a severe recurrent frontal headache often associated with loss of consciousness occurring after at least 2 hours of pain. The MRI and CSF findings were consistent with subarachnoid bleeding. In our patient, headache due to meningeal irritation by subarachnoid blood induced seizures as a probable reflex of extreme pain. Carbamazepine and nimodipine prophylaxis dramatically reduced the frequency of headaches and seizures.

Entities:  

Mesh:

Year:  1999        PMID: 11279963     DOI: 10.1046/j.1526-4610.1999.3909666.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  3 in total

1.  Superficial siderosis of the central nervous system with seizures onset.

Authors:  Chun-Yong Chen; Fang Xiao; Jing-Li Liu
Journal:  Singapore Med J       Date:  2015-10       Impact factor: 1.858

2.  Epilepsy caused by superficial hemosiderosis of the central nervous system.

Authors:  Zeljka Petelin Gadze; Davorka Milat; Filip Derke; Marija Bosnjak Pasic; Ervina Bilic
Journal:  Neurol Sci       Date:  2017-11-05       Impact factor: 3.307

3.  Two Unusual Cases of Headache: Superficial Siderosis Coexisting with Migraine.

Authors:  Arpan Dutta; Souvik Dubey; Alak Pandit; Goutam Gangopadhyay
Journal:  Ann Indian Acad Neurol       Date:  2021-05-11       Impact factor: 1.383

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.